TEW 7197

Drug Profile

TEW 7197

Alternative Names: EW-7197; NOV 1301; TEW7197

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ewha Womans University
  • Developer Case Comprehensive Cancer Center; MedPacto; National OncoVenture
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 07 Nov 2017 TEW 7197 is still in phase I trials for Solid tumours (Late-stage disease) in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Tablet)
  • 21 Jul 2017 Phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03143985)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top